



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


# PRODUCT INFORMATION



PF-04753299

Item No. 36502

CAS Registry No.: 1289620-49-0  
Formal Name: N-hydroxy- $\alpha$ R-methyl- $\alpha$ -(methylsulfonyl)-  
[1,1'-biphenyl]-4-butanamide  
MF: C<sub>18</sub>H<sub>21</sub>NO<sub>4</sub>S  
FW: 347.4  
Purity:  $\geq$ 98%  
Supplied as: A solid  
Storage: -20°C  
Stability:  $\geq$ 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

PF-04753299 is supplied as a solid. A stock solution may be made by dissolving the PF-04753299 in the solvent of choice, which should be purged with an inert gas. PF-04753299 is soluble in the organic solvent DMSO at a concentration of approximately 34.7 mg/ml.

## Description

PF-04753299 is an inhibitor of LpxC (IC<sub>50</sub> = 1.37 nM), a bacterial deacetylase involved in the biosynthesis of LPS lipid A.<sup>1</sup> It is selective for LpxC over a panel of 16 human matrix metalloproteinases (MMPs; K<sub>i</sub>s = >1 μM for all). PF-04753299 is active against *P. aeruginosa*, *K. pneumoniae*, *E. coli*, *E. aerogenes*, *C. freundii*, and *A. baumannii* (MIC<sub>90</sub>s = 4, 16, 2, 4, 8, and 32 μg/ml, respectively). *In vivo*, PF-04753299 reduces splenic bacterial burden in a mouse model of systemic *P. aeruginosa* infection (ED<sub>50</sub> = 35 mg/kg).

## Reference

1. Brown, M.F., Reilly, U., Abramite, J.A., *et al.* Potent inhibitors of LpxC for the treatment of Gram-negative infections. *J. Med. Chem.* **55**(2), 914-923 (2012).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM